Startup profile for Earli: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Earli funding, valuation and investors

Synthetic biopsy biotech — forces tumors to produce detectable biomarkers for early cancer localization.

Keep track of Earli

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$40M · January 2021

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$60M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · South San Francisco, California

Investors in latest funding

Lead: Khosla Ventures

Other: Andreessen Horowitz , Menlo Ventures

Sources: latest funding Last verified: 2026-07-25

Overview

Earli develops synthetic biopsy technology that forces tumors to produce detectable biomarkers — enabling ultra-early cancer localization without invasive tissue sampling. Stanford-licensed platform raised $19.5M seed in 2018 led by a16z Bio+Health with Marc Benioff and $40M Series A in January 2021 led by Khosla Ventures with a16z and Menlo Ventures participating.

Why Earli is interesting

Stanford-licensed platform — Khosla led Series A with Menlo and a16z Bio as synthetic biopsy advances toward clinic.

Product & use cases

Engineered genetic constructs injected to make tumors produce synthetic biomarkers detectable in blood — 'forcing' cancer to reveal its location.

  • Early cancer detection and localization via blood test
  • Non-invasive alternative to surgical biopsy for tumor mapping
  • Monitoring treatment response through synthetic biomarker levels

Key facts

  • Series A (Jan 2021): $40M led by Khosla; a16z, Menlo (BusinessWire)
  • Seed (2018): $19.5M led by a16z Bio+Health
  • Stanford-licensed synthetic biopsy technology

Funding history (newest first)

Series A

2021-01 $40M

Source: https://www.businesswire.com/news/earli-series-a

Seed

2018 $19.5M

Source: https://www.businesswire.com/news/earli-seed

Investors in our directory

Funds linked from Earli's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Khosla Ventures Menlo Ventures

Competitive landscape

Edge: Novel synthetic biopsy approach vs. traditional liquid biopsy detecting natural shed markers.

Early cancer detection is crowded but synthetic biopsy is differentiated — forcing signal vs. passive detection. Clinical validation is the gating milestone.

  • Grail (Galleri) adjacent

    Multi-cancer early detection blood test.

  • Guardant Health adjacent

    Liquid biopsy for cancer monitoring.

  • Freenome adjacent

    Blood-based colorectal cancer screening.

  • Traditional biopsy incumbent

    Invasive tissue sampling; gold standard for diagnosis.

Notable stories

  • Earli's approach 'forces' tumors to produce synthetic biomarkers — flipping the liquid biopsy model from passive detection to active signaling (BusinessWire, 2021).

Industries

Biotech & Life Sciences Healthtech

FAQs about Earli

Practical answers founders, operators, and investors typically search for.

Synthetic biopsy — forces tumors to produce detectable biomarkers for early cancer localization.
Khosla (/fund/khosla-ventures) led Series A. a16z (/fund/andreessen-horowitz) led seed. Menlo (/fund/menlo-ventures) participated.
Engineered constructs make tumors produce synthetic markers detectable in blood.
Grail detects natural shed markers; Earli actively forces tumor signaling.
Seed 2018 ($19.5M), Series A 2021 ($40M).
South San Francisco, California.
Advancing toward clinic per company materials — check earli.com for current status.
Not disclosed. Clinical-stage biotech.
No.
Cancer survival correlates strongly with stage at diagnosis — Earli targets localization before metastasis.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.